Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price

 
• By Neena Brizmohun

Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.

Lymphoma
Kymriah is now recommended for use on NHS Scotland for DLBCL. • Source: Shutterstock

More from Archive

More from Pink Sheet